azd4547
Small moleculeexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started May 31, 2016 (NCT04439240)
Timeline
Indications
Mechanism of action
- Fibroblast growth factor receptor 3INHIBITOR
FGFR3 inhibitor
- Fibroblast growth factor receptor 2INHIBITOR
FGFR2 inhibitor
- Fibroblast growth factor receptor 1INHIBITOR
FGFR1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05775874 | Phase 2 | Sep 30, 2022 | Abbisko Therapeutics Co, Ltd, Fudan University |
| NCT05086666 | Phase 1/Phase 2 (Phase 2) | Jun 3, 2021 | Abbisko Therapeutics Co, Ltd |
| NCT04439240 | Phase 2 | May 31, 2016 | ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI) |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Abbisko Therapeutics Co, Ltd | For profit | 2 | 2 | 1 | 2021 |
| ECOG-ACRIN Cancer Research Group | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Fudan University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 2016 |
4 organizations
Page 1 / 1